Revised Un-audited Financial Results for the quarter ended on 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
Skybiotech Healthcare (formerly Kapil Cotex) has refiled its Q2/H1 FY26 results, with the revision only to include the consolidated balance sheet and cash flow statement that were missing in the original submission. On a standalone basis, the company remains a very small operation with revenue of just Rs 1.54 lakhs in Q2 FY26 and a marginal profit of Rs 1.17 lakhs. The real activity sits in subsidiary Skybiotech Life Sciences (revenue Rs 194 lakhs, loss Rs 32 lakhs in Q2). On a consolidated basis, H1 FY26 revenue grew about 22% to Rs 430.47 lakhs (vs Rs 351.21 lakhs a year ago), but the company slipped back into a loss of Rs 89.18 lakhs against a small profit last year, and the full-year FY25 had already ended with a loss of Rs 236.97 lakhs. Consolidated cash and bank balance remains negative at Rs -13.72 lakhs as of September 30, 2025. The company name was also changed from Kapil Cotex to Skybiotech Healthcare on the MCA portal on November 7, 2025.
Negative for shareholders — the consolidated business is loss-making again in H1 FY26, revenue growth has not translated into profitability, and the company is sitting on a negative cash balance, suggesting ongoing cash burn even as it acquires a new healthcare identity.